Treatment Outcomes for Serious Infections Caused by Methicillin‐Resistant<i>Staphylococcus aureus</i>with Reduced Vancomycin Susceptibility

Howden, Benjamin P; Ward, Peter; Charles, Patrick G P; Korman, Tony M.; Fuller, Andrew; Cros, Philipp du; Grabsch, Elizabeth A; Roberts, Sally; Robson, Jenny; Read, Kerry; Bak, Narin; Hurley, James C.; Johnson, Paul D R; Morris, Arthur J.; Mayall, Barrie C.; Grayson, M Lindsay

doi:10.1086/381202

Cited by 466 publications

(318 citation statements)

References 18 publications

Supporting

Mentioning

300

Contrasting

Unclassified

Order By: Relevance

“…Occasionally, such a combination can be a treatment option for heterogeneous vancomycin-intermediate S. aureus (hVISA) or VISA infections (19), as supported by our finding that fusidic acid plus rifampin is effective in decreasing bacterial loads in the biofilm model. In addition, the frequency of rifampin-resistant mutations in the presence of fusidic acid and rifampin in S. aureus is lower than that seen with rifampin monotherapy (10 Ϫ11 versus Ͻ10 Ϫ8 ) (20).…”

mentioning

confidence: 64%

In Vitro Efficacies and Resistance Profiles of Rifampin-Based Combination Regimens for Biofilm-Embedded Methicillin-Resistant Staphylococcus aureus

Tang

Chen

Cheng

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

f To compare the in vitro antibacterial efficacies and resistance profiles of rifampin-based combinations against methicillin-resistant Staphylococcus aureus (MRSA) in a biofilm model, the antibacterial activities of vancomycin, teicoplanin, daptomycin, minocycline, linezolid, fusidic acid, fosfomycin, and tigecycline alone or in combination with rifampin against biofilm-embedded MRSA were measured. The rifampin-resistant mutation frequencies were evaluated. Of the rifampin-based combinations, rifampin enhances the antibacterial activities of and even synergizes with fusidic acid, tigecycline, and, to a lesser extent, linezolid, fosfomycin, and minocycline against biofilm-embedded MRSA. Such combinations with weaker rifampin resistance induction activities may provide a therapeutic advantage in MRSA biofilm-related infections.

show abstract

mentioning

confidence: 64%

In Vitro Efficacies and Resistance Profiles of Rifampin-Based Combination Regimens for Biofilm-Embedded Methicillin-Resistant Staphylococcus aureus

Tang

Chen

Cheng

et al. 2013

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Recently, the incidence of infections due to MRSA with elevated VCM-MIC has been reported to be increasing in association with treatment failure and poor outcomes (18)(19)(20)(21). Strains with a VCM-MIC of 2-4 μg/mL had previously been categorized as VCM-sensitive strains, but are now considered to have intermediate susceptibility (22).…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Persistent MRSA Bacteremia using High-dose Daptomycin Combined with Rifampicin

et al. 2014

View full text Add to dashboard Cite

We herein report a case of persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia that was successfully treated with combination therapy consisting of high-dose daptomycin (DAP, 10 mg/kg) and rifampicin. The patient's condition was complicated with multiple infectious foci, including an iliopsoas abscess and epidural abscess, as well as discitis and spondylitis at the cervical, thoracic and lumbar levels. Monotherapy treatments with vancomycin, linezolid and usual-dose DAP were all ineffective. It has been shown that usual-dose DAP administration may result in the emergence of a resistant strain and treatment failure. We would like to emphasize the importance of high-dose DAP therapy for MRSA bacteremia, a condition with a potentially high mortality rate.

show abstract

“…A rabbit model of quinupristin/dalfopristin prosthetic joint infection with MRSA was compared to vancomycin with or without rifampicin, showing an equivalent outcome. 86 …”

Section: Bone and Joint Infectionsmentioning

confidence: 99%

Novel pharmaceutical molecules against emerging resistant gram-positive cocci

Manfredi¹,

Sabbatani²

2010

Braz J Infect Dis

View full text Add to dashboard Cite

Introduction: methicillin-and also vancomycin (glycopeptide)-resistant Gram-positive organisms have emerged as an increasingly problematic cause of hospital-acquired infections, also spreading into the community. Vancomycin (glycopeptide) resistance has emerged primarily among Enterococci, but the MIC values of vancomycin for the entire Staphylococcus species are also increasing worldwide. Material and Methods: the aim of our review is to evaluate the efficacy and tolerability of newer antibiotics with activity against methicillin-resistant and glycopeptide-resistant Gram-positive cocci, on the ground of our experience at a tertiary care metropolitan Hospital, and the most recent literature evidences in this field. Results: Quinupristin-dalfopristin, linezolid, daptomycin, and tigecycline show an excellent in vitro activity, comparable to the activity of vancomycin and teicoplanin for methicillin-resistant staphylococci, and superior to the one that vancomycin for vancomycin-resistant isolates. Dalbavancin, televancin, and oritavancin are new lipoglycopeptide agents with excellent activity against Gram-positive cocci, and have superior pharmacodynamics properties compared to vancomycin. We review the bacterial spectrum, clinical indications and practical use, pharmacologic properties, and expected adverse events and contraindications associated with each of these novel antimicrobial agents, compared with the present standard of care. Discussion: linezolid activity is substantially comparable to that of vancomycin in patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, although its penetration into the respiratory tract is exceptionally elevated. Tigecycline has activity against both Enterococus species and MRSA; it is also active against a broad spectrum of Enterobacteriaceae and anaerobes, which allows for use intraabdominal, diabetic foot and surgical infections. Daptomycin has a rapid bactericidal activity for Staphylococcus aureus and it is approved in severe complications, such as bacteremia and right-sided endocarditis. It cannot be used to treat pneumonia and respiratory diseases, due to its inactivation in the presence of pulmonary surfactant.

show abstract

Treatment Outcomes for Serious Infections Caused by Methicillin‐ResistantStaphylococcus aureuswith Reduced Vancomycin Susceptibility

Cited by 466 publications

References 18 publications

In Vitro Efficacies and Resistance Profiles of Rifampin-Based Combination Regimens for Biofilm-Embedded Methicillin-Resistant Staphylococcus aureus

In Vitro Efficacies and Resistance Profiles of Rifampin-Based Combination Regimens for Biofilm-Embedded Methicillin-Resistant Staphylococcus aureus

Successful Treatment of Persistent MRSA Bacteremia using High-dose Daptomycin Combined with Rifampicin

Novel pharmaceutical molecules against emerging resistant gram-positive cocci

Contact Info

Product

Resources

About